Indian drugmaker Cipla tops Q2 profit view on solid domestic, N.America sales

Total revenue from operations rose nearly 15 per cent to 66.78 billion rupees, led by a 13.4 per cent growth in its mainstay pharmaceutical business, said Cipla, which makes generic respiratory and cancer drugs along with consumer-branded products such as pain reliever Omnigel.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/FZvQS5C
via